Zenocutuzumab Shows Clinical Benefit in Rare Bile Duct Cancer
October 22, 2025
October 22, 2025
PHILADELPHIA, Pennsylvania, Oct. 22 [Category: Medical] -- The American Association for Cancer Research posted the following news release:
* * *
Zenocutuzumab Shows Clinical Benefit in Rare Bile Duct Cancer
*
BOSTON - Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 (NRG1)-positive cholangiocarcinoma, accordi . . .
* * *
Zenocutuzumab Shows Clinical Benefit in Rare Bile Duct Cancer
*
BOSTON - Zenocutuzumab (Bizengri), a bispecific antibody that targets human epidermal growth factor receptor 2 (HER2) and HER3, led to responses in more than a third of patients with neuregulin 1 (NRG1)-positive cholangiocarcinoma, accordi . . .